Abrdn Life Sciences Investors (NYSE:HQL - Get Free Report) was the recipient of a large increase in short interest in the month of December. As of December 31st, there was short interest totalling 77,800 shares, an increase of 212.4% from the December 15th total of 24,900 shares. Based on an average daily trading volume, of 93,900 shares, the short-interest ratio is currently 0.8 days.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Penserra Capital Management LLC purchased a new stake in shares of Abrdn Life Sciences Investors in the 3rd quarter valued at approximately $11,702,000. Needham Investment Management LLC increased its holdings in Abrdn Life Sciences Investors by 3.2% in the third quarter. Needham Investment Management LLC now owns 352,719 shares of the company's stock valued at $5,319,000 after buying an additional 10,904 shares during the last quarter. Cetera Investment Advisers increased its holdings in Abrdn Life Sciences Investors by 6.9% in the second quarter. Cetera Investment Advisers now owns 156,384 shares of the company's stock valued at $2,216,000 after buying an additional 10,137 shares during the last quarter. Commonwealth Equity Services LLC raised its stake in Abrdn Life Sciences Investors by 2.6% in the second quarter. Commonwealth Equity Services LLC now owns 33,788 shares of the company's stock valued at $479,000 after buying an additional 868 shares in the last quarter. Finally, International Assets Investment Management LLC purchased a new stake in Abrdn Life Sciences Investors during the 3rd quarter worth about $204,000. 32.21% of the stock is currently owned by hedge funds and other institutional investors.
Abrdn Life Sciences Investors Price Performance
Abrdn Life Sciences Investors stock traded down $0.18 during mid-day trading on Tuesday, reaching $13.25. 139,265 shares of the company's stock were exchanged, compared to its average volume of 125,396. Abrdn Life Sciences Investors has a twelve month low of $12.76 and a twelve month high of $15.90. The company has a fifty day moving average of $13.97 and a 200-day moving average of $14.67.
Abrdn Life Sciences Investors Increases Dividend
The business also recently disclosed a quarterly dividend, which was paid on Friday, January 10th. Stockholders of record on Thursday, November 21st were paid a $0.50 dividend. This is a boost from Abrdn Life Sciences Investors's previous quarterly dividend of $0.49. This represents a $2.00 annualized dividend and a dividend yield of 15.09%. The ex-dividend date was Thursday, November 21st.
About Abrdn Life Sciences Investors
(
Get Free Report)
Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.
See Also
Before you consider Abrdn Life Sciences Investors, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abrdn Life Sciences Investors wasn't on the list.
While Abrdn Life Sciences Investors currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
